[Feasibility of adjuvant docetaxel plus cyclophosphamide therapy for breast cancer].
OBJECTIVE
To evaluate the feasibility of adjuvant docetaxel plus cyclophosphamide(TC)therapy for breast cancer.


METHODS
A total of 16 patients with intermediate risk-breast cancer were enrolled. TC therapy consisted of four courses of docetaxel 75 mg/m² plus cyclophosphamide 600 mg/m² intravenous administration over three weeks. Every infusion was premedicated with intravenous administration of granisetron 3 mg plus dexamethasone 16 mg, followed by dexamethasone 8 mg p. o. on days 2 and 3.


RESULTS
Due to the allergic reaction, one patient discontinued TC therapy. Fifteen (94%) of the 16 patients completed the scheduled TC therapy. Feasibility was 93.7%. Grade 3/4 toxicity was limited to leucopenia, neutropenia, and febrile neutropenia. No non-hematological serious adverse events were observed.


CONCLUSIONS
Adjuvant TC therapy is a feasible option for breast cancer.
Naito
Koma
K
Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University.
Oura
Shoji
S
Yoshimasu
Tatsuya
T
Nakamura
Rie
R
Hirai
Yoshimitsu
Y
Kiyoi
Megumi
M
Miyasaka
Miwako
M
Okamura
Yoshitaka
Y
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077143:Docetaxel; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D043823:Taxoids; D000077143:Docetaxel; D003520:Cyclophosphamide